Hosted on MSN9d
Why Verona Pharma, A Triple-Digit Gainer In 2024, Surged Another 19% This Week
Verona Pharma stock hit a record high Thursday on continued enthusiasm for its newly launched COPD treatment, Ohtuvayre.
Verona Pharma stock target upgraded, retains buy on Q4 results
H.C. Wainwright analyst increased the price target on shares of Verona Pharma (NASDAQ:VRNA) to $60 from the previous target of $42, maintaining a Buy rating on the shares.
Verona Pharma price target raised to $60 from $42 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Verona Pharma (VRNA) to $60 from $42 and keeps a Buy rating on the ...
Verona Pharma’s Ohtuvayre: Strong Performance and Growth Potential Drive Buy Rating
Verona Pharma (VRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from ...
Verona Pharma stock soars to all-time high of $51.88
In a remarkable display of market confidence, Verona Pharma (NASDAQ:VRNA)'s stock has surged to an all-time high, reaching a ...